An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C
Phase of Trial: Phase III/IV
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TRICO
- Sponsors Roche
- 26 Aug 2014 The actual patient number is 165 as per ClinicalTrials.gov record but EudraCT gives the number as 150. I have retained NCT info as it is recently updated.
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver